Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Piperazines administration & dosage"" wg kryterium: Temat


Wyświetlanie 1-12 z 12
Tytuł :
Treatment of advanced HR+/HER2− breast cancer with new targeted agents in combination with endocrine therapy:a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib
Autorzy :
Bøttcher, Tea M.
Cold, Søren
Jensen, Anders B.
Pokaż więcej
Temat :
Aminopyridines/administration & dosage
Antineoplastic Agents, Hormonal/administration & dosage
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Benzimidazoles/administration & dosage
Breast Neoplasms/drug therapy
Disease Progression
Drugs, Investigational/therapeutic use
Everolimus/administration & dosage
Female
Humans
Molecular Targeted Therapy/methods
Piperazines/administration & dosage
Purines/administration & dosage
Pyridines/administration & dosage
Randomized Controlled Trials as Topic/statistics & numerical data
Receptor, ErbB-2/genetics
Receptors, Cytoplasmic and Nuclear/genetics
Treatment Outcome
Źródło :
Bøttcher, T M, Cold, S & Jensen, A B 2019, ' Treatment of advanced HR+/HER2− breast cancer with new targeted agents in combination with endocrine therapy : a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib ', Acta Oncologica, vol. 58, no. 2, pp. 147-153 . https://doi.org/10.1080/0284186X.2018.1532603
Tytuł :
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
Autorzy :
Paik, Paul K
Shen, Ronglai
Berger, Michael F
Ferry, David
Soria, Jean-Charles
Mathewson, Alastair
Rooney, Claire
Smith, Neil R
Cullberg, Marie
Kilgour, Elaine
Landers, Donal
Frewer, Paul
Brooks, Nigel
André, Fabrice
Pokaż więcej
Temat :
Benzamides/administration & dosage
Neoplasm Staging
Aged
Middle Aged
Receptor, Fibroblast Growth Factor, Type 1/genetics
Treatment Outcome
Genetic Heterogeneity
Antineoplastic Agents/administration & dosage
Neoplasm Grading
Chromosomes, Human, Pair 8
Sequence Analysis, DNA
Carcinoma, Squamous Cell/drug therapy
Piperazines/administration & dosage
Neoplasm Metastasis
stomatognathic diseases
Female
Gene Expression Profiling
Lung Neoplasms/drug therapy
Humans
Gene Amplification
Male
Pyrazoles/administration & dosage
Źródło :
Paik, P K, Shen, R, Berger, M F, Ferry, D, Soria, J-C, Mathewson, A, Rooney, C, Smith, N R, Cullberg, M, Kilgour, E, Landers, D, Frewer, P, Brooks, N & André, F 2017, ' A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 23, no. 18, pp. 5366-5373 . https://doi.org/10.1158/1078-0432.CCR-17-0645
Tytuł :
Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study.
Autorzy :
Tanguy-Schmidt, Aline
Rousselot, Philippe
Chalandon, Yves
Cayuela, Jean-Michel
Hayette, Sandrine
Vekemans, Marie-Christiane
Escoffre, Martine
Huguet, Françoise
Réa, Delphine
Delannoy, André
Cahn, Jean-Yves
Vernant, Jean-Paul
Ifrah, Norbert
Dombret, Hervé
Thomas, Xavier
Pokaż więcej
Temat :
Unrelated Donors
MESH: Male
MESH: Philadelphia Chromosome
MESH: Age Factors
MESH: Piperazines
MESH: Pyrimidines
MESH: Time Factors
MESH: Disease-Free Survival
Benzamides/administration & dosage/adverse effects
MESH: Hematopoietic Stem Cell Transplantation
Time Factors
hemic and lymphatic diseases
[SDV.CAN]Life Sciences [q-bio]/Cancer
MESH: Transplantation, Autologous
MESH: Transplantation, Homologous
Hematopoietic Stem Cell Transplantation
Survival Rate
MESH: Female
MESH: Adult
Female
Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality/therapy
MESH: Precursor Cell Lymphoblastic Leukemia-Lymphoma
MESH: Antineoplastic Agents
MESH: Adolescent
ddc:616
Age Factors
MESH: Humans
Piperazines/administration & dosage/adverse effects
Middle Aged
Pyrimidines/administration & dosage/adverse effects
Hematology
Antineoplastic Agents/administration & dosage/adverse effects
Follow-Up Studies
MESH: Follow-Up Studies
Disease-Free Survival
Transplantation
MESH: Middle Aged
MESH: Unrelated Donors
Adolescent
Transplantation, Autologous
MESH: Survival Rate
MESH: Benzamides
Adult
Philadelphia Chromosome
Humans
Male
Transplantation, Homologous
Źródło :
Biology of Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation, Vol. 19, No 1 (2013) pp. 150-5
Biology of Blood and Marrow Transplantation, Elsevier, 2013, 19 (1), pp.150-5. ⟨10.1016/j.bbmt.2012.08.021⟩
Tytuł :
Seksuel dysfunktion i menopausen. Status over forekomst, farmakologiske behandlingsmuligheder og risici
Sexual dysfunction in the menopause. Incidence, pharmacological treatment and side effects
Autorzy :
Gregersen, Nina
Hilmand, Christina Bjerre
Jensen, Pernille Tine
Giraldi, Annamaria G Elena
Pokaż więcej
Temat :
Adult
Androgens/administration & dosage
Estrogen Receptor Modulators/administration & dosage
Estrogen Replacement Therapy/adverse effects
Female
Humans
Incidence
Libido/drug effects
Menopause/drug effects
Middle Aged
Norpregnenes/administration & dosage
Phosphodiesterase Inhibitors/administration & dosage
Piperazines/administration & dosage
Postmenopause/drug effects
Purines
Risk Factors
Sexual Dysfunction, Physiological/drug therapy
Sildenafil Citrate
Sulfones
Testosterone/administration & dosage
Źródło :
Gregersen, N, Hilmand, C B, Jensen, P T & Giraldi, A G E 2006, ' Seksuel dysfunktion i menopausen. Status over forekomst, farmakologiske behandlingsmuligheder og risici ', Ugeskrift for laeger, bind 168, nr. 6, s. 559-63 .
    Wyświetlanie 1-12 z 12

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies